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Abstract
HPV vaccination rates among adolescents in the United States lag behind some other developed
countries, many of which routinely offer the vaccine in schools. We sought to assess mothers’
willingness to have their adolescent daughters receive HPV vaccine at school. A national sample
of mothers of adolescent females ages 11–14 completed our internet survey (response rate = 66%).
The final sample (n = 496) excluded mothers who did not intend to have their daughters receive
HPV vaccine in the next year. Overall, 67% of mothers who intended to vaccinate their daughters
or had vaccinated their daughters reported being willing to have their daughters receive HPV
vaccine at school. Mothers were more willing to allow their daughters to receive HPV vaccine in
schools if they had not yet initiated the vaccine series for their daughters or resided in the Midwest
or West (all p < .05). The two concerns about voluntary school-based provision of HPV vaccine
that mothers most frequently cited were that their daughters’ doctors should keep track of her
shots (64%) and that they wished to be present when their daughters were vaccinated (40%). Our
study suggests that most mothers who support adolescent vaccination for HPV find school-based
HPV vaccination an acceptable option. Ensuring communication of immunization records with
doctors and allowing parents to be present during immunization may increase parental support.
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Widespread uptake of human papillomavirus (HPV) vaccine has the potential to prevent the
majority of cervical cancer cases [1]. As cervical cancer disproportionately affects minority,
rural, and low income women [2,3], vaccination is particularly important for these groups.
National guidelines recommend routine HPV vaccination for girls ages 11 or 12 and catch-
up doses for females ages 13–26 who have not yet been vaccinated [4]. However, as of
2009, only 44% of eligible girls ages 13–17 in the United States have received at least one
dose of HPV vaccine, and 27% have received all three doses [5].
School-based provision of HPV vaccine in other countries has proven successful at
achieving broad coverage. In the first year after HPV vaccine was added to existing school
immunization programs, parts of Australia achieved initiation rates of over 80% among
female students ages 12–18 [6-8]. In parts of Australia with follow-up data, fewer students
completed all three doses, but coverage still remained sizeable, generally ranging from 60 to
75% [6-8]. In British Columbia, Canada, 65% of eligible 11-year-old girls received the first
dose of HPV vaccine when it was offered through a publicly funded school-based vaccine
program [9]. The United Kingdom and Sweden have also successfully begun offering HPV
vaccination through school health programs [10,11].
Clearly, the U.S. has a more complex, fragmented health care delivery system than these
other countries. As such, billing and insurance issues pose an impediment to broader school-
based immunization programs as do costs to schools and health departments for
implementing such programs. In the U.S., school-based health care varies widely by state,
and even within states, from nonexistent care to comprehensive health programs offered by
school health centers. In a national study of U.S. schools, only 14% regularly offered any
kind of vaccination for students [12]. Although most schools with comprehensive school
health centers offer vaccinations [13], only 6% of school districts nationwide have at least
one school health center of that nature [12].
Nonetheless, increasing the prevalence of U.S. school-based vaccination programs might
improve HPV vaccine coverage of children and teenagers. In a population-based sample in
North Carolina, most (62%) parents of unvaccinated daughters intended to vaccinate them
against HPV during the coming year [14]. However, on longitudinal follow-up, less than
40% of these parents actually did so, and barriers to care (i.e. believing that it would be
difficult to find a provider who stocked the vaccine or who offered the vaccine at an
affordable price) were associated with lower uptake [15]. If school vaccination programs
could address these barriers, they might increase vaccine receipt among daughters of parents
who intend to vaccinate but fail to follow through. Further, because schools offer the
possibility of reaching low-income students [13] and students who are not otherwise
accessing preventative care [16], they could reduce disparities in cervical cancer incidence
and mortality by targeting areas and populations with high rates of the disease.
To address whether school-based HPV vaccination could remove barriers and provide an
acceptable option for parents, we surveyed mothers who got or intended to get HPV vaccine
for their daughters about their willingness to let their daughters receive HPV vaccine at
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school. We also assessed mothers’ potential concerns about school-based HPV vaccine
provision.
2. Materials and methods
2.1. Study design
We used data from a nationally representative sample of mothers of adolescent females ages
11–14 who were members of an existing panel of U.S. households [17]. The panel was
composed using list-assisted, random-digit dialing, supplemented by address-based
sampling for homes with no landline, which provided a probability-based sample of U.S.
households [17]. Panel members received free internet access and a small payment in
exchange for completing multiple internet-based surveys each month. Households without
pre-existing internet were provided a laptop computer and internet access. The Institutional
Review Board at the University of North Carolina approved the study.
The survey company invited 1681 mothers to complete our cross-sectional, online survey.
Among those mothers, 1170 opened the email invitation, and 1009 had a daughter ages 11–
14, making them eligible to participate in the study. A total of 951 mothers of 11–14 year-
old females completed the survey in December 2009 (response rate = 66%, calculated using
the American Association for Public Opinion Research response rate formula 4 [18]).
Participants were more likely than non-participants to have a college degree, but they did not
differ on 6 other key sociodemographic characteristics available for non-participants. In
order to understand mothers’ support for school-based HPV vaccination specifically, rather
than support for HPV vaccination more generally, for this analysis we excluded mothers (n
= 443) who did not intend to vaccinate daughters against HPV in the next year and thus
included only mothers who had vaccinated or intended to vaccinate daughters in the coming
year. We also excluded respondents who had missing data on willingness to get their
daughters vaccinated at school (n = 7) or who indicated that daughters were homeschooled
(n = 5), resulting in an analytic sample of 496 mothers.
2.2. Measures
The survey (available at www.unc.edu/~ntbrewer/hpv.htm) assessed willingness to
vaccinate daughters at school with the question “If [daughter name]’s school offered HPV
vaccine, how willing would you be to let her get it there?” We categorized mothers as
willing to allow their daughters to get vaccinated at school if they responded they were
“definitely” or “probably” willing and categorized them as unwilling if they responded they
were “definitely not” or “probably not” willing. Mothers also indicated whether they had
any of 6 specific concerns or no concerns about school vaccination.
Current HPV vaccination status had three categories. The “not initiated” group included
daughters who had not received any HPV shots but whose mothers intended for them to be
vaccinated in the next year. Daughters in the “initiated” group included those who
previously received one shot, two shots, or an unknown number of shots. The “completed”
vaccine group included those daughters who had received all 3 HPV vaccine shots.
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Four survey items assessed HPV vaccine knowledge: HPV vaccine prevents most genital
warts, prevents most cases of cervical cancer, is recommended for 11- or 12-year-old girls,
and works best if girls get it before they start having sex. We created an index by calculating
the proportion of correct answers for each respondent (possible range 0–1, with higher
values indicating greater knowledge). Four items assessed mothers’ satisfaction with their
daughters’ health care: the daughter’s health care is of good quality, the mother is getting
needed information about daughter’s health or health care, the doctor spends enough time
with daughter, and the doctor is a trusted source of advice. We averaged these items to
create a satisfaction scale (possible range 1–5, with higher values indicating greater
satisfaction (α = 0.85)). The survey also assessed demographic correlates including being
politically conservative and born-again or evangelical Christian, as concerns about HPV
vaccine have often come from these groups[15,19].
2.3. Data analyses
We examined bivariate correlates of willingness to have daughter receive HPV vaccine at
school using logistic regression. All correlates identified as statistically significant (p < .05)
in bivariate analyses were included in a multivariate model. We examined the percentage of
mothers who endorsed each of the school vaccination concerns, comparing those who were
willing to vaccinate at school to those who were not willing using chi-square tests. We also
used chi-square tests to examine the association between each concern and vaccination
status (i.e., mother intended to vaccinate daughter vs. daughter had received one more doses
of HPV vaccine). We analyzed weighted data in Stata SE version 10.0 (Statacorp, College
Station, TX) applying sampling weights. Frequencies are unweighted and estimates
(including proportions and odds ratios) are weighted. All analyses were two-tailed, using a
critical α of .05.
3. Results
Most mothers were 40 years old or older (55%), non-Hispanic white (55%), married (76%),
did not have a college degree (74%), lived in urban areas (85%), and reported a household
income of less than $60,000 (55%; Table 1). Approximately one-third (34%) indicated they
were born-again or evangelical Christian. Most daughters (93%) had health insurance.
Twenty percent of mothers reported that their daughters had completed the 3-dose series of
HPV vaccine shots, 31% that daughters had initiated but not completed the series (only 1 or
2 shots), and 48% that they intended to vaccinate daughters in the next year. Twelve mothers
who said their daughters initiated the vaccine series but did not know how many doses they
had received were included in the “initiated” group. Analyses do not change meaningfully
when these 12 cases are omitted.
Overall, 67% of mothers who intended to vaccinate their daughters or had vaccinated their
daughters reported being willing to have their daughters receive HPV vaccine at school
(Table 2). Multivariate correlates of willingness to vaccinate at school were daughter’s HPV
vaccination status and region of residence. Mothers whose daughters had completed the 3-
dose series were less accepting of school vaccination than mothers whose daughters had not
initiated the vaccine series, (56% vs. 76%, OR 0.46, 95% CI 0.22, 0.97). Mothers whose
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daughters had not initiated the vaccine series did not differ in support from those who had
initiated but not yet completed the series. Compared to mothers residing in the Northeast,
willingness to have daughters vaccinated at school was higher among mothers in the
Midwest (OR 2.56, 95% CI 1.20, 5.43) or West (OR 3.03, 95% CI 1.51, 6.12).
Mothers’ most common concern about in-school vaccination was that the daughter’s doctor
should keep track of her shots and other health history (64%). When stratified by willingness
to vaccinate at school (Fig. 1), more mothers who were unwilling were concerned about
doctors’ keeping track of daughters’ health records than mothers who were willing (84% vs.
54%, p < .001). As one might expect, more mothers who were unwilling to vaccinate at
school felt that schools should not provide vaccinations and fewer said that they had no
concerns about in-school vaccination, when compared to mothers who approved of in-
school HPV vaccination (each p < .001). Concerns about being present during vaccination
(40%), staff training (30%), and insurance coverage (18%) were less commonly cited and
did not differ by willingness. More mothers who intended to vaccinate daughters were
concerned about being present during vaccination than those whose daughters had received
one or more doses of HPV vaccine (47% vs. 33%, p < .05).
4. Discussion
With less than half of eligible girls having initiated HPV vaccine [5], the U.S. should
promote additional vaccine implementation strategies to increase uptake. School-based
vaccination has been successful in generating broad HPV vaccination coverage in other
countries [7-11], and our findings suggest that the majority of U.S. mothers who support
HPV vaccination find school-based vaccination an acceptable option. Among mothers who
had already gotten or intended to get HPV vaccine for their daughters, two-thirds were
willing to have their daughters receive the vaccine at school.
Mothers whose daughters had already completed the 3-dose HPV vaccine series had
somewhat less favorable attitudes toward HPV vaccination at school than mothers who had
not initiated the vaccine series for their daughters but intended to do so. The former group
might have indicated lower acceptability because they interpreted the question as referring
to receipt of additional doses (>3) of the vaccine after the series had already been completed.
Alternatively, mothers whose daughters had already completed the vaccination series may
have done so precisely because of greater comfort with vaccine administration in a health
care provider’s office. Thus, they may prefer this setting over a school.
Concerns about HPV vaccine provision in schools did differ between those who were
willing and unwilling to vaccinate at school. The vast majority of mothers who were
unwilling to have their daughters receive HPV vaccine at school were concerned about their
daughters’ physicians keeping track of their health records, and this may be a difficult issue
to address. Although many states have immunization information systems, also known as
state vaccination registries, not all private providers participate in these systems, and the
comprehensiveness of systems differs from state to state [20]. Moreover, schools do not
always participate in these registries, and identifying students in the registries and updating
their vaccination data requires time and effort from staff.
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A substantial proportion of all mothers wanted to be there when their daughters were
vaccinated, and more mothers who intended to vaccinate daughters endorsed this concern
compared to mothers whose daughters had some or all shots. Allowing mothers to be present
during in-school vaccination would allay some concern. However, as many mothers did not
have this concern, requiring parental attendance for vaccination may be unduly burdensome
and could reduce vaccine uptake. Being present for vaccination can also mean substantial
lost time at jobs for working parents [21].
Some mothers were concerned about the level of staff training and insurance coverage for
in-school vaccination. These concerns did not differ by willingness to vaccinate at school,
suggesting that they are basic concerns that may not be related specifically to HPV vaccine.
To make school-based vaccination more feasible, schools where staff have sufficient
training to administer vaccines should reassure parents by describing that training. Insurance
coverage for in-school vaccination may vary by insurance plan, but children eligible for the
Vaccines for Children program should be able to receive many vaccines, including HPV
vaccine, at no cost.
Initiating school-based HPV vaccination programs in the U.S. is likely to be challenging, as
the nature and extent of health care offered at schools varies widely [22]. Even when
community vaccinators are brought into schools to provide services or school-based
programs are coordinated through health departments, barriers include obtaining vaccination
records to see which vaccines are needed, billing private insurance, covering students who
do not qualify for the federal Vaccines for Children program, and obtaining parental consent
for vaccination [13]. Although schools with health centers will receive increased federal
funding through the Patient Protection and Affordable Care Act [23], many of these barriers
will remain and will be undoubtedly amplified for programs that will not receive additional
funding through the new law.
Furthermore, past experience with school vaccination programs in the U.S. suggests that
they tend to be most successful when they are implemented in response to acute outbreaks or
to deliver vaccines mandated for school admissions [22], neither of which generally apply to
HPV vaccine in the U.S. School-based programs to vaccinate against Hepatitis B in the
1990s were extremely successful, but these programs were by and large demonstration
projects, intended to cover the gap until routine infant vaccine administration and school-
entry laws ensured widespread coverage [24,25].
Finally, any school-based program must overcome challenges posed by competing priorities
and limited resources in the nation’s schools. In response to these challenges, current
recommendations for promoting adolescent vaccination in schools include: integrating
vaccine information into existing health curricula; disseminating vaccine information to
parents via existing channels, such as parent newsletters; working with school nurses and
other school personnel to build support; and forming coalitions with community partners,
such as school board representatives, health department staff, and pediatricians [22].
Requiring HPV vaccination for school entry could circumvent many of the problems
described above and is another strategy with potential to dramatically increase vaccine
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coverage; however, policymakers in the U.S. have adopted this approach only rarely to date,
as such requirements have been controversial. Opponents have argued that HPV school
immunization requirements infringe on parental autonomy and have decried the vaccine as
unnecessary, unsafe, or implicitly encouraging teenage sexual activity [26-28]. Between
2007 and 2010, 24 states and the District of Columbia proposed legislation requiring HPV
vaccination for girls entering sixth grade, but the legislation failed or was withdrawn in a
host of states, including Michigan, Ohio, Texas, California, and Maryland [29]. To date,
Washington DC and Virginia are the only jurisdictions that have enacted requirements, but
both allow parents to easily opt out of the requirement for any reason [29,30]. In the absence
of school requirements in most states, voluntary school-based HPV vaccination remains a
central strategy to explore, and understanding parental attitudes toward school-based HPV
vaccination is an important first step.
Parental support will be crucial to implementing school-based provision of HPV vaccine.
School policy decisions in the U.S., including whether to allow vaccination programs in
schools, are typically made at the local level by school administrators, including principals
and superintendants. Parents are key stakeholders in decisions about school health programs
and can influence administrators’ judgments about controversial topics [22]. Understanding
parental support for providing HPV vaccine in schools will be important for planning
implementation of new policies. It is important to remember that our analytic sample did not
include mothers who indicated that they would not vaccinate their daughters against HPV in
the coming year. We chose this strategy in order to differentiate attitudes toward school-
based HPV vaccination from attitudes toward HPV vaccination in any setting. However,
excluding these mothers prevents us from fully characterizing parental support for school-
based HPV vaccination policies.
Strengths of this study include the sizeable nationally representative sample and timeliness
of the topic for informing new public health programs. However, unfamiliarity with school-
based health care in general rather than to opposition to school-based HPV vaccination
specifically may inform some parents’ responses, given that school-based health care is
relatively uncommon in the U.S. As we did not assess whether daughters attended public or
private schools or whether daughters had access to school-based clinics, we were not able to
examine the impact of these variables on mothers’ willingness to let their daughters receive
HPV vaccine at school.
5. Conclusions
School-based HPV vaccination programs in other countries have been successful in
increasing vaccine coverage rates. Findings from this study suggest that many U.S. parents
who support vaccination against HPV would be willing to vaccinate their adolescent
daughters at school. However, parental acceptance is only one of many barriers to school-
based vaccination, perhaps less important than structural barriers like identifying correct
payers for billing or maintaining up-to-date vaccination records across multiple vaccine
administration settings. With school policy controlled at the local level and the health care
and health insurance systems fragmented, the initiation of a widespread school-based
vaccination program in the U.S. is not on the immediate horizon. In the mean-time, more
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research is needed to understand and address parental concerns about the administration of
HPV vaccine in schools and to identify steps to address structural barriers.
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Mothers’ (n = 496) concerns about allowing their daughters to receive HPV vaccine at
school, according to willingness to vaccinate at school. *p < .001.
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Table 1




 11 years 117 (26.9)
 12 years 91 (17.2)
 13 years 132 (25.0)
 14 years 156 (30.9)
Has health insurance
 No 19 (6.8)
 Yes 477 (93.2)
Has a regular healthcare provider
 No 15 (3.3)
 Yes 481 (96.8)
HPV vaccine 3 dose series
 Not initiated 224 (48.4)
 Initiated
a 153 (31.4)
 Completed 119 (20.3)
Mother characteristics
Age
 <40 years 162 (45.1)
 40–49 years 270 (47.0)
 50+ years 64 (8.0)
Race/ethnicity
 Non-Hispanic white 365 (54.5)
 Non-Hispanic black 47 (17.3)
 Hispanic or other 84 (28.1)
Education
 No college degree 272 (74.0)
 College degree or higher 224 (26.0)
Marital status
 Other 97 (23.7)
 Married 399 (76.3)
Political views
 Somewhat or very conservative 176 (37.7)
 Moderate 201 (44.1)
 Somewhat or very liberal 119 (18.1)
Born-again or evangelical Christian
 No 351 (65.6)
 Yes 145 (34.4)
Satisfaction with daughter’s medical care, mean (SD)
b 4.23 (0.74)
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Ever talked with daughter about HPV vaccine
 No 105 (26.1)
 Yes 391 (73.9)




 <$60,000 180 (55.2)
 $60,000+ 316 (44.9)
Area of residence
d
 Rural 61 (15.1)
 Urban 435 (84.9)
Region
 Northeast 85 (16.3)
 Midwest 153 (22.4)
 South 136 (40.8)
 West 122 (20.5)
Number of children in household
 1–2 337 (62.3)
 3 or more 159 (37.7)
Note: Table shows raw frequencies and weighted percentages. Percentages may not total 100% due to rounding. HPV = human papillomavirus; SD
= standard deviation.
a
Includes 12 parents who said their daughter initiated the vaccine but did not know how many doses. Analyses do not change meaningfully when
these 12 cases are omitted.
b
Mean score on health care satisfaction scale. Component items included mother’s satisfaction with daughter’s healthcare (range: 1 =very
dissatisfied to 5=very satisfied) and mother’s beliefs (range: 1 =strongly disagree to 5 = strongly agree) that she is getting needed information about
daughter’s health or health care, the doctor spends enough time with daughter, and the doctor is a trusted source of advice.
c
Proportion of correct responses on 4 HPV vaccine knowledge items (range: 0-1). Component items included knowledge that HPV vaccine:
prevents most genital warts, prevents most cervical cancer, is recommended for 11- or 12-year-old girls, and works best if girls get it before they
start having sex.
d
Rural defined as living outside of a metropolitan statistical area (Census Bureau Glossary http://factfinder.census.gov/home/en/epss/
glossary_r.html).
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Table 2
Correlates of willingness to have daughter receive HPV vaccine at school (n = 496).
Willing to vaccinate at school Bivariate Multivariate




 11 years (Ref) 79 (74.2) 1.00 - 1.00 -
 12 years 64 (74.6) 1.02 (0.40, 2.63) 1.16 (0.46, 2.93)
 13 years 73 (50.2) 0.35 (0.15, 0.80)* 0.52 (0.24, 1.12)
 14 years 106 (69.6) 0.80 (0.35,1.84) 1.09 (0.46, 2.59)
Has health insurance
 No (Ref) 14 (82.7) 1.00 -
 ;Yes 308 (65.7) 0.40 (0.11,1.45)
Has a regular healthcare provider
 No (Ref) 11 (73.4) 1.00 -
 Yes 311 (66.6) 0.72 (0.19, 2.77)
HPV vaccine 3 dose series
 Not initiated (Ref) 158 (76.4) 1.00 - 1.00 -
 Initiated
a 97 (59.2) 0.45 (0.22, 0.91)* 0.60 (0.30, 1.23)
 Completed 67 (55.8) 0.39 (0.19, 0.79)** 0.46 (0.22, 0.97)*
Mother characteristics
Age
 <40 years (Ref) 102 (68.3) 1.00 -
 40–49 years 173 (62.9) 0.79 (0.42,1.47)
 50+ years 47 (81.7) 2.07 (0.93, 4.59)
Race
 Non-Hispanic white (Ref) 234 (65.0) 1.00 -
 Non-Hispanic black 30 (64.8) 0.99 (0.40, 2.48)
 Hispanic or other 58 (71.6) 1.25 (0.62, 3.00)
Education
 Some college or less (Ref) 182 (69.1) 1.00 -
 Bachelors degree or more 140 (60.3) 0.68 (0.40, 1.16)
Marital status
 Other (Ref) 72 (75.3) 1.00 -
 Married 250 (64.2) 0.59 (0.26,1.35)
Political views
 Conservative (Ref) 107 (61.3) 1.00 -
 Moderate 134 (68.8) 1.39 (0.70, 2.76)
 Liberal 81 (73.6) 1.76 (0.86,3.61)
Born-again or evangelical Christian
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Willing to vaccinate at school Bivariate Multivariate
n (%) OR (95% CI) OR (95% CI)
 No (Ref) 240 (65.7) 1.00 -
 Yes 82 (69.0) 1.16 (0.63, 2.14)
Satisfaction with daughter’s medical care, mean (SD)
b 4.17 (0.78) 0.74 (0.48,1.13)
Ever talked with daughter about HPV vaccine
 No (Ref) 75 (78.3) 1.00 -
 Yes 247 (62.8) 0.47 (0.22,1.01)
HPV vaccine knowledge, mean (SD)
c 0.48 (0.32) 0.33 (0.12, 0.95)* 0.49 (0.17, 1.43)
Household characteristics
Annual household income
 <$60,000 (Ref) 123 (71.3) 1.00 -
 $60,000+ 199 (61.3) 0.64 (0.35,1.15)
Area of residence
 Rural (Ref) 43 (69.7) 1.00 -
 Urban 279 (66.3) 0.86 (0.33, 2.19)
Region
 Northeast (Ref) 47 (47.3) 1.00 - 1.00 -
 South 85 (71.4) 2.36 (1.04, 5.36)* 1.91 (0.89, 4.10)
 Midwest 103 (68.0) 2.79 (1.28, 6.05)* 2.56 (1.20, 5.43)*
 West 87 (75.0) 3.34 (1.54, 7.23)" 3.03 (1.51,6.12)"
Number of children in household
 1–2 (Ref) 223 (69.1) 1.00 -
 3 or more 99 (63.0) 0.76 (0.41,1.43)
Note: Table shows raw frequencies and weighted estimates. Percentages may not total 100% due to rounding. Multivariate model contains all
correlates significant (p<.05) in bivariate models. HPV = human papillomavirus; CI = confidence interval; OR = odds ratio; Ref= reference
category; SD = standard deviation.
a
Includes 12 parents who said their daughter initiated the vaccine but did not know how many doses. Analyses do not change meaningfully when
these 12 cases are omitted.
b
Mean score on health care satisfaction scale. Component items included mother’s belief that: daughter’s health care is of good quality, she is
getting needed information about daughter’s health or health care, the doctor spends enough time with daughter, and the doctor is a trusted source
of advice.
c
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